Compare Stocks → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BFRINASDAQ:CMMBNASDAQ:ITRMNASDAQ:MACKNASDAQ:SPRB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$1.69+1.8%$1.39$0.61▼$13.42$8.60M0.83638,713 shs25,769 shsCMMBChemomab Therapeutics$0.66-1.5%$0.73$0.42▼$1.89$7.28M0.36190,684 shs11,539 shsITRMIterum Therapeutics$1.57+1.3%$1.51$0.62▼$2.50$25.80M2.36501,690 shs50,845 shsMACKMerrimack Pharmaceuticals$14.73+0.1%$14.71$11.53▼$15.89$214.03M1.43110,789 shs82,841 shsSPRBSpruce Biosciences$0.70$2.44$0.67▼$5.95$28.85M2.521.11 million shs377,244 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera+1.81%+1.20%+52.25%+11.92%-84.91%CMMBChemomab Therapeutics-1.64%-5.86%-12.02%+31.80%-56.93%ITRMIterum Therapeutics+1.29%+9.79%+0.64%-8.72%+57.00%MACKMerrimack Pharmaceuticals+0.14%+0.34%+0.07%+11.17%+21.23%SPRBSpruce Biosciences-0.11%0.00%+0.14%-79.38%-66.30%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRIBiofrontera1.8029 of 5 stars3.53.00.00.01.10.01.3CMMBChemomab Therapeutics2.0942 of 5 stars3.35.00.00.00.01.70.6ITRMIterum Therapeutics1.2106 of 5 stars3.53.00.00.00.60.00.6MACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASPRBSpruce Biosciences3.4784 of 5 stars4.15.00.00.00.02.51.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera3.00Buy$18.00965.09% UpsideCMMBChemomab Therapeutics2.67Moderate Buy$7.00962.22% UpsideITRMIterum Therapeutics3.00Buy$6.00282.17% UpsideMACKMerrimack PharmaceuticalsN/AN/AN/AN/ASPRBSpruce Biosciences2.25Hold$5.67708.37% UpsideCurrent Analyst RatingsLatest SPRB, MACK, ITRM, CMMB, and BFRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/14/2024SPRBSpruce BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $3.003/14/2024SPRBSpruce BiosciencesLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/14/2024SPRBSpruce BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral3/14/2024SPRBSpruce BiosciencesSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$9.00 ➝ $2.003/14/2024SPRBSpruce BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$9.00 ➝ $2.003/14/2024SPRBSpruce BiosciencesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral3/14/2024SPRBSpruce BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral3/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/5/2024SPRBSpruce BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.002/26/2024SPRBSpruce BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $9.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$34.07M0.25N/AN/A$3.16 per share0.53CMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/ASPRBSpruce Biosciences$10.09M2.86N/AN/A$1.88 per share0.37Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$20.13M-$15.82N/AN/AN/A-59.09%-344.98%-72.85%5/10/2024 (Estimated)CMMBChemomab Therapeutics-$24.22M-$2.12N/AN/AN/AN/A-114.00%-88.53%5/9/2024 (Confirmed)ITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)MACKMerrimack Pharmaceuticals-$1.18M-$0.08N/A∞N/AN/A-6.24%-6.09%5/2/2024 (Estimated)SPRBSpruce Biosciences-$47.92M-$1.25N/AN/AN/A-474.96%-52.31%-39.77%5/20/2024 (Estimated)Latest SPRB, MACK, ITRM, CMMB, and BFRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/ACMMBChemomab Therapeutics-$0.20N/A+$0.20N/AN/AN/A3/28/2024Q4 2023ITRMIterum Therapeutics-$1.02-$0.94+$0.08-$0.94N/AN/A3/15/2024Q4 2023BFRIBiofronteraN/A-$2.33-$2.33-$6.31N/A$10.60 million3/13/2024Q4 2023SPRBSpruce Biosciences-$0.41-$0.23+$0.18-$0.23$1.65 million$2.89 million3/7/202412/31/2023CMMBChemomab Therapeutics-$0.40-$0.26+$0.14-$0.26N/AN/A 3/7/2024Q4 2023MACKMerrimack PharmaceuticalsN/A-$0.01-$0.01-$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofronteraN/A1.280.67CMMBChemomab TherapeuticsN/A4.324.32ITRMIterum Therapeutics3.631.891.89MACKMerrimack PharmaceuticalsN/A43.5043.50SPRBSpruce Biosciences0.024.184.18OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%CMMBChemomab Therapeutics46.05%ITRMIterum Therapeutics9.21%MACKMerrimack Pharmaceuticals63.97%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipBFRIBiofrontera0.69%CMMBChemomab Therapeutics11.91%ITRMIterum Therapeutics5.40%MACKMerrimack Pharmaceuticals28.87%SPRBSpruce Biosciences9.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera835.09 million5.05 millionNo DataCMMBChemomab Therapeutics2011.05 million9.73 millionNot OptionableITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableMACKMerrimack Pharmaceuticals42614.53 million10.34 millionOptionableSPRBSpruce Biosciences2941.15 million37.41 millionOptionableSPRB, MACK, ITRM, CMMB, and BFRI HeadlinesSourceHeadlineSpruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meetingbusinesswire.com - April 22 at 4:05 PMSpruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by Analystsamericanbankingnews.com - April 20 at 4:34 AMIMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 19 at 4:00 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 5 at 7:00 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBprnewswire.com - April 4 at 7:15 PMONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 4 at 7:00 AMONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 3 at 3:30 AMONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 1 at 6:00 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 30 at 6:20 PMIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 29 at 5:00 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 28 at 3:30 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBprnewswire.com - March 27 at 5:36 PMSpruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Knowzacks.com - March 27 at 1:01 PMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 27 at 3:30 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 26 at 3:30 AMONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 25 at 4:30 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 24 at 7:00 AMRevenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)finance.yahoo.com - March 23 at 10:38 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 23 at 7:00 AMINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 22 at 7:00 AMHoldings A/S Novo Sells 359,979 Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) Stockinsidertrades.com - March 22 at 6:24 AMSpruce Biosciences (SPRB) Falls 86% in a Month: Here's Whyzacks.com - March 21 at 11:21 AMIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 21 at 3:30 AMIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 20 at 7:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiofronteraNASDAQ:BFRIBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Chemomab TherapeuticsNASDAQ:CMMBChemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Merrimack PharmaceuticalsNASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Spruce BiosciencesNASDAQ:SPRBSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.